Flexible Semaglutide Titration Regimen Proposed to Mitigate GI Adverse Events in Type 2 Diabetes

Treatment for type 2 diabetes mellitus (T2DM) often involves glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide, which improve glycemic control. However, a significant challenge with GLP-1RAs is the high incidence of gastrointestinal adverse events (GI-AEs), including nausea, vomiting, and diarrhea, which can impact patient adherence and quality of life. The current label-recommended dose escalation regimen for semaglutide, typically over 8 weeks, may contribute to these side effects. Exploring alternative, slower titration schedules is crucial to enhance tolerability and optimize patient outcomes.

This trial plans to compare two semaglutide titration regimens in patients with type 2 diabetes mellitus. The study will evaluate a 16-week flexible semaglutide titration regimen against the current 8-week label-recommended dose escalation regimen. The primary objective is to assess the effect of the slower titration on the occurrence of GI-AEs, which are commonly observed during GLP-1 receptor agonist treatment. The study design aims to identify if a more gradual increase in dosage can improve patient tolerability.